Novartis AG (NVS) Shares Bought by Fairfield Bush & CO.

Fairfield Bush & CO. lifted its stake in shares of Novartis AG (NYSE:NVS) by 0.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 94,812 shares of the company’s stock after acquiring an additional 110 shares during the period. Novartis AG makes up 2.5% of Fairfield Bush & CO.’s investment portfolio, making the stock its 11th biggest position. Fairfield Bush & CO.’s holdings in Novartis AG were worth $7,914,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Stonebridge Capital Advisors LLC lifted its holdings in shares of Novartis AG by 2.3% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 25,323 shares of the company’s stock worth $2,114,000 after acquiring an additional 567 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Novartis AG by 26.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 116,921 shares of the company’s stock worth $9,760,000 after acquiring an additional 24,596 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Novartis AG by 0.5% during the 2nd quarter. Assetmark Inc. now owns 93,777 shares of the company’s stock worth $7,828,000 after acquiring an additional 455 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Novartis AG by 11.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,343 shares of the company’s stock worth $348,000 after acquiring an additional 434 shares during the last quarter. Finally, Roberts Glore & Co. Inc. IL lifted its holdings in shares of Novartis AG by 1.3% during the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 12,705 shares of the company’s stock worth $1,060,000 after acquiring an additional 165 shares during the last quarter. 10.92% of the stock is owned by institutional investors.

A number of research firms have recently issued reports on NVS. BidaskClub downgraded shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Cowen and Company set a $90.00 price objective on shares of Novartis AG and gave the stock a “hold” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday. Finally, Zacks Investment Research downgraded shares of Novartis AG from a “buy” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $85.12.

TRADEMARK VIOLATION WARNING: “Novartis AG (NVS) Shares Bought by Fairfield Bush & CO.” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/10/novartis-ag-nvs-shares-bought-by-fairfield-bush-co.html.

Novartis AG (NVS) traded up 0.15% during trading on Tuesday, hitting $85.58. 691,268 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $84.91 and a 200 day moving average price of $81.57. The company has a market cap of $200.50 billion, a price-to-earnings ratio of 31.24 and a beta of 0.73. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The business had revenue of $12.24 billion during the quarter, compared to analyst estimates of $12.20 billion. During the same quarter last year, the business earned $1.23 earnings per share. Novartis AG’s quarterly revenue was down 1.8% compared to the same quarter last year. On average, equities research analysts predict that Novartis AG will post $4.75 earnings per share for the current year.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit